Top

Published in:

01-05-2012 | Review

Immune regulation of procalcitonin: a biomarker and mediator of infection

Authors: G. N. Matwiyoff, J. D. Prahl, R. J. Miller, J. J. Carmichael, D. E. Amundson, G. Seda, M. Daheshia

Published in: Inflammation Research | Issue 5/2012

Abstract

Procalcitonin (PCT) has recently emerged as a powerful biomarker for an early and accurate diagnosis of bacterial infection. Here we summarize our current understanding of the expression pathways of PCT, its potential cellular sources including immune cells, and factors inducing its secretion. Also addressed is the significance of increased blood PCT concentration, which may allow this molecule not only to act as a clinical biomarker but also as an active participant in the development and progression of infectious processes. Experimental approaches to delineate a better understanding of PCT functions, molecular pathways that modulate its expression and therapeutic opportunities to curtail its biological actions are discussed, as well.

Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8.PubMedCrossRef

Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, de Moraes MA, Ricchetti SM. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res. 2010;59(8):581–6.PubMedCrossRef

Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–17.PubMedCrossRef

Gendrel D, Bohuon C. Procalcitonin in pediatrics for differentiation of bacterial and viral infections. Intensive Care Med. 2000;26(Suppl 2):S178–81.PubMed

Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract. 2011;2011:594645.PubMed

Lai CC, Tan CK, Chen SY, Wang CY, Liu WL, Hou CC, Hsueh PR. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 2010;61(6):512–5.PubMedCrossRef

Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003;112(5):1054–60.PubMedCrossRef

Kim MH, Lim G, Kang SY, Lee WI, Suh JT, Lee HJ. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011;52(2):276–81.PubMedCrossRef

Wunder C, Eichelbrönner O, Roewer N. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res. 2004;53(4):158–63.PubMedCrossRef

10.

Nylén ES, Snider RH Jr, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 1996;312(1):12–8.PubMedCrossRef

11.

Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M, Raftogiannis M, Antonakos N. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011;26(3):331.e1–7.CrossRef

12.

Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.PubMedCrossRef

13.

Becker KL, Snider R, Nylén ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010;159(2):253–64.PubMedCrossRef

14.

Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K. Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med. 1999;37(8):789–97.PubMedCrossRef

15.

Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci. 1990;28(2):109–74.PubMedCrossRef

16.

Peleg S, Abruzzese RV, Cote GJ, Gagel RF. Transcription of the human calcitonin gene is mediated by a C cell-specific enhancer containing E-box-like elements. Mol Endocrinol. 1990;4(11):1750–7.PubMedCrossRef

17.

Peleg S. Modified binding of proteins from calcitonin-negative tumor cells to the neuroendocrine-specific CANNTG motif of the calcitonin gene. Nucleic Acids Res. 1993;21(23):5360–5.PubMedCrossRef

18.

Monla YT, Peleg S, Gagel RF, Monia YT. Cell type-specific regulation of transcription by cyclic adenosine 3′,5′-monophosphate-responsive elements within the calcitonin promoter. Mol Endocrinol. 1995;9(7):784–93.PubMedCrossRef

19.

Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med. 1997;45(9):552–60.PubMed

20.

Bolko P, Manuszewska-Jopek E, Michałek K, Waśko R, Jaskuła M, Sowiński J. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz). 2003;51(6):415–9.

21.

Nishikura T. Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med. 1999;25(9):1031.PubMedCrossRef

22.

Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, Suarez-Domenech V, Bergmann A, Müller B. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35(5):290–5.PubMedCrossRef

23.

Domenech VS, Nylen ES, White JC, Snider RH, Becker KL, Landmann R, Müller B. Calcitonin gene-related peptide expression in sepsis: postulation of microbial infection-specific response elements within the calcitonin I gene promoter. J Investig Med. 2001;49(6):514–21.PubMedCrossRef

24.

Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.PubMedCrossRef

25.

Giunti M, Peli A, Battilani M, Zacchini S, Militerno G, Otto CM. Evaluation of CALC-I gene (CALCA) expression in tissues of dogs with signs of the systemic inflammatory response syndrome. J Vet Emerg Crit Care (San Antonio). 2010;20(5):523–7.CrossRef

26.

Meisner M, Müller V, Khakpour Z, Toegel E, Redl H. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model. Shock. 2003;19(2):187–90.PubMedCrossRef

27.

Silomon M, Bach F, Ecker D, Graeter T, Grundmann U, Larsen R. Procalcitonin after extracorporeal circulation. Synthesis in the hepatosplanchnic region. Anaesthesist. 1999;48(6):395–8.PubMedCrossRef

28.

Kretzschmar M, Krüger A, Schirrmeister W. Procalcitonin following elective partial liver resection—origin from the liver? Acta Anaesthesiol Scand. 2001;45(9):1162–7.PubMedCrossRef

29.

Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134(1):49–55.PubMedCrossRef

30.

Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61(2):180–6.PubMedCrossRef

31.

Kuzi S, Aroch I, Peleg K, Karnieli O, Klement E, Dank G. Canine procalcitonin messenger RNA expression. J Vet Diagn Invest. 2008;20(5):629–33.PubMedCrossRef

32.

Oberhoffer M, Vogelsang H, Jäger L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care. 1999;14(1):29–33.PubMedCrossRef

33.

Balog A, Ocsovszki I, Mándi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett. 2002;84(3):199–203.PubMedCrossRef

34.

Monneret G, Laroche B, Bienvenu J. Procalcitonin is not produced by circulating blood cells. Infection. 1999;27(1):34–5.PubMedCrossRef

35.

Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–84.PubMedCrossRef

36.

Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32(8):1715–21.PubMedCrossRef

37.

Koivula I, Hämäläinen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, et al. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis. 2011;43(6–7):471–8.PubMedCrossRef

38.

Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res. 2010;59(5):339–47.PubMedCrossRef

39.

Miedema KG, de Bont ES, Elferink RF, van Vliet MJ, Nijhuis CS, Kamps WA, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2010. [Epub ahead of print].

40.

Hatzistilianou M, Rekleity A, Athanassiadou F, DeLutiis MA, Conti P, Catriu D. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007;30(2):E75–85.PubMed

41.

Axer H, Wohlfarth M, Meisner M, Finn S, Ragoschke-Schumm A, Mentzel HJ, et al. Procalcitonin as a marker for severe sepsis in an immunosuppressed patient. Anasthesiol Intensivmed Notfallmed Schmerzther. 2005;40(2):97–102.PubMedCrossRef

42.

Al-Nawas B, Shah PM. Procalcitonin in patients with and without immunosuppression and sepsis. Infection. 1996;24(6):434–6.PubMedCrossRef

43.

Picariello C, Lazzeri C, Valente S, Chiostri M, Attanà P, Gensini GF. Kinetics of procalcitonin in cardiogenic shock and in septic shock. Preliminary data. Acute Card Care. 2010;12(3):96–101.PubMedCrossRef

44.

Clodi M, Vila G, Geyeregger R, Riedl M, Stulnig TM, Struck J, Luger TA, et al. Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab. 2008;295(3):E686–91.PubMedCrossRef

45.

Preas HL 2nd, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001;184(3):373–6.PubMedCrossRef

46.

Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–8.PubMedCrossRef

47.

Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S, et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis. 2008;26(8):38.CrossRef

48.

Kim KE, Han JY. Evaluation of the clinical performance of an automated procalcitonin assay for the quantitative detection of bloodstream infection. Korean J Lab Med. 2010;30(2):153–9.PubMedCrossRef

49.

von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23(7):539–44.CrossRef

50.

Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28(2):458–61.PubMedCrossRef

51.

Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag PM. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000;28(4):1040–6.PubMedCrossRef

52.

Whang KT, Vath SD, Becker KL, Snider RH, Nylen ES, Muller B, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock. 2000;14(1):73–8.PubMedCrossRef

53.

Papassotiriou I, Alexiou VG, Tsironi M, Skenderi K, Spanos A, Falagas ME. Severe aseptic inflammation caused by long distance running (246 km) does not increase procalcitonin. Eur J Clin Invest. 2008;38(4):276–9.PubMedCrossRef

54.

Chakrabartty S, Apong S. Procalcitonin estimation in Kawasaki disease. Indian Pediatr. 2009;46(7):648.PubMed

55.

Barati M, Alinejad F, Bahar MA, Tabrisi MS, Shamshiri AR, Bodouhi NO, Karimi H. Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns. 2008;34(6):770–4.PubMedCrossRef

56.

Latour-Pérez J, Alcalá-López A, García-García MA, Sánchez-Hernández JF, Abad-Terrado C, Viedma-Contreras JA, et al. Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. Clin Biochem. 2010;43(9):720–4.PubMedCrossRef

57.

Dahaba AA, Hagara B, Fall A, Rehak PH, List WF, Metzler H. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth. 2006;97(4):503–8.PubMedCrossRef

58.

Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396–402.PubMed

59.

Steinwald PM, Whang KT, Becker KL, Snider RH, Nylen ES, White JC. Elevated calcitonin precursor levels are related to mortality in an animal model of sepsis. Crit Care. 1999;3(1):11–6.PubMedCrossRef

60.

Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26(6):1001–6.PubMedCrossRef

61.

Wagner KE, Martinez JM, Vath SD, Snider RH, Nylén ES, Becker KL, et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med. 2002;30(10):2313–21.PubMedCrossRef

62.

Tavares E, Miñano FJ. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci (Lond). 2010;119(12):519–34.CrossRef

63.

Martinez JM, Wagner KE, Snider RH, Nylen ES, Muller B, Sarani B. Late immunoneutralization of procalcitonin arrests the progression of lethal porcine sepsis. Surg Infect (Larchmt). 2001;2(3):193–202. discussion 202–203.CrossRef

64.

Liappis AP, Gibbs KW, Nylen ES, Yoon B, Snider RH, Gao B, et al. Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res. 2011;60(2):203–7.PubMedCrossRef

65.

Wei JX, Verity A, Garle M, Mahajan R, Wilson V. Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery. Br J Anaesth. 2008;100(5):612–21.PubMedCrossRef

66.

Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30(5):1112–7.PubMedCrossRef

67.

Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39(2):127–32.PubMedCrossRef

68.

Pincíková T, Bucová M, Slobodníková L. Influence of recombinant human procalcitonin on phagocytic and candidacidal ability of polymorphonuclear leukocytes and on killing mechanisms of serum and blood against bacteria Staphylococcus aureus and Escherichia coli. Vnitr Lek. 2005;51(12):1365–70.PubMed

69.

Monneret G, Pachot A, Laroche B, Picollet J, Bienvenu J. Procalcitonin and calcitonin gene-related peptide decrease LPS-induced tnf production by human circulating blood cells. Cytokine. 2000;12(6):762–4.PubMedCrossRef

70.

Bucova M, Zahorec R, Buc M. Immunomodulatory effect of recombinant human procalcitonin on mitogenic activity of lymphocytes. Cent Eur J Immunol. 2006;31:87–93.

71.

Hoffmann G, Schobersberger W. Anti-inflammatory procalcitonin (PTC) in a human whole blood model septic shock. Cytokine. 2000;12(6):762–4.CrossRef

72.

Hoffmann G, Totzke G, Seibel M, Smolny M, Wiedermann FJ, Schobersberger W. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin. Crit Care Med. 2001;29(1):112–6.PubMedCrossRef

73.

Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med. 2002;30(9):2091–5.PubMedCrossRef

74.

Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia. 2011. [Epub ahead of print].

75.

Jereb M, Lunaček NK, Kotar T, Saksida A, Petrovec M, Avšič-Županc T. Procalcitonin in hantavirus infections. Scand J Clin Lab Invest. 2011;71(4):287–91.PubMedCrossRef

76.

Christ-Crain M, Müller B. Procalcitonin and pneumonia: is it a useful marker? Curr Infect Dis Rep. 2007;9(3):233–40.PubMedCrossRef

77.

Becker KL, Bivins LE, Radfar RH, Snider RH, Moore CF, Silva OL. Study of calcitonin heterogeneity using a radioreceptor assay. Horm Metab Res. 1978;10(5):457–8.PubMedCrossRef

78.

Jullienne A, Raulais D, Calmettes C, Moukhtar MS, Milhaud G. Heterogeneity of immunoreactive calcitonin in normal human thyroid. Horm Metab Res. 1978;10(5):456–7.PubMedCrossRef

79.

Sexton PM, Christopoulos G, Christopoulos A, Nylen ES, Snider RH Jr, Becker KL. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med. 2008;36(5):1637–40.PubMedCrossRef

Title: Immune regulation of procalcitonin: a biomarker and mediator of infection
Authors: G. N. Matwiyoff
J. D. Prahl
R. J. Miller
J. J. Carmichael
D. E. Amundson
G. Seda
M. Daheshia
Publication date: 01-05-2012
Publisher: SP Birkhäuser Verlag Basel
Published in: Inflammation Research / Issue 5/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-012-0439-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

MiRNA-140 is a negative feedback regulator of MMP-13 in IL-1β-stimulated human articular chondrocyte C28/I2 cells

Contribution of gender and body fat distribution to inflammatory marker concentrations in apparently healthy young adults

Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide

Barrier protective activities of curcumin and its derivative

The association between the functional PTPN22 1858 C/T and MIF −173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis

Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials